ENERGYNEST
30.3.2017 14:32:09 CEST | Business Wire | Press release
Tata Steel operates one of Europe’s largest steel production facilities in IJmuiden / Netherlands. Currently, large energy potentials are released to the atmosphere, through intermittent high temperature exhaust gases. Implicit economic benefits of this waste heat remain untapped. Finding an effective way to recover and reuse this energy will not only yield attractive economic returns, but also significant CO2 emission reductions.
In order to fully utilize such effects, Tata Steel is now commencing the implementation of an EnergyNest Thermal Energy Storage (TES) demo project as a ‘lighthouse initiative’. The IJmuiden demo will utilize exhaust gas energy from steel production to cover own energy demands in the facility – resulting in reduced natural gas consumption and CO2 emissions.
“The steel industry has already undertaken huge efforts to reduce emissions, and to go any further simply requires new technologies. This demo installation is just a first step for Tata’s IJmuiden plant. We are proud to be yet again the global leader for implementing environmentally friendly solutions with a strong business case.” says Gerard Jägers, Program Manager Energy Efficiency. A joint assessment of effects for a full-scale implementation of the EnergyNest throughout the IJmuiden facility shows impressive results: a 500 MWh TES can yield annual savings of 2.3 million GJ of natural gas (65 million Nm3 ) and 130.000 tons of emitted CO2 . EnergyNest CEO Dr. Christian Thiel: “These savings compensate for annual CO2 emissions of 90.000 cars. And at the same time a full-scale implementation offers extremely attractive economics, which supplement such a project with a very healthy business rationale. We are very proud to support Tata Steel in its game-changing approach towards carbon footprint reduction.”
The EnergyNest TES technology is based on globally available materials that are fully recyclable. Due to its very low cost-base, a full-scale implementation in the IJmuiden facility – together with Jord as acting EPC – has a payback of less than three years, based on today’s natural gas prices. Should natural gas prices increase the payback period is reduced to less than two years. Adopting this innovative technology, Tata Steel IJmuiden will strengthen the facility's status as a global technology frontrunner.
About EnergyNest: EnergyNest (EN) is a technology company based in Billingstad, close to the Norwegian capital Oslo. Founded in 2011, EN has developed a unique and patented design for a modular solid-state thermal energy storage (“TES”) systems and a tailored solid state storage medium (HEATCRETE®) that enables a very simple, efficient, and low cost energy storage system (“EN technology”). The EN technology can be applied in various market segments, that require high temperature thermal energy storage for many hours or days. EN’s technology is field proven at the Masdar Institute, UAE.
About Tata Steel: Tata Steel is one of the world leading manufacturers of raw steel, rolled and coated products. It is also one of the world’s most geographically diversified steel producers, serving many demanding markets worldwide, including Aerospace, Automotive, Construction, Consumer Products, Defence & Security, Energy & Power, Lifting & Excavating and Packaging. Tata Steel is committed to the design of more sustainable products that contribute to solutions, which are lighter, last longer and use fewer resources to produce.
About Jord: Jord Oil & Gas Systems B.V. is a Rotterdam based company that designs, manufactures, commissions, and services custom-engineered process equipment, modular skids, and turnkey plants for the steel, oil and gas, chemical and petrochemical industries.
View source version on businesswire.com: http://www.businesswire.com/news/home/20170330005611/en/
Contact:
EnergyNest
Thomas Palkovich
Commercial Director
Mob:
+47 982 08 384
Email: tp@energy-nest.com
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Yubico Appoints Poupak Modirassari Enbom as Chief Marketing Officer to Accelerate Global Momentum and Drive Market Leadership30.3.2026 15:00:00 CEST | Press release
Yubico (NASDAQ STOCKHOLM: YUBICO), the creator of the most secure passkeys and a leading provider of hardware authentication security keys, today announced the appointment of Poupak Enbom as Chief Marketing Officer (CMO). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260330278027/en/ Enbom joins Yubico at a pivotal moment as organizations worldwide accelerate the shift to phishing-resistant authentication and modern identity security in the age of AI. “We’re excited to welcome Poupak to Yubico,” said Jerrod Chong, acting chief executive officer, Yubico. “As the threat landscape evolves with AI-driven attacks and increasing automation, organizations are rethinking how they secure digital identities of both humans and AI agents at scale. She brings a unique combination of technical depth, global leadership, and customer-first mindset that will help us continue to expand our impact and support our customers and partners around
Westinghouse Celebrates Record-breaking 80 Years of Nuclear Fuel Manufacture at Springfields30.3.2026 14:00:00 CEST | Press release
Fuel manufactured at Springfields has generated enough energy to supply the UK’s electricity demand for 26 years, avoiding the emission of nearly 3 billion tonnes of CO2 The Westinghouse Springfields facility in Lancashire, UK, has marked a significant milestone as the oldest continuous nuclear fuel manufacturing site in the world, starting from its original license on the 28th, March 1946. The site was chosen by the UK Government to develop nuclear fuel for the world’s earliest civil nuclear power stations, as well as subsequent Magnox and Advanced Gas Reactors (AGR) reactors. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260330135973/en/ From left to right: Sophie Lemaire; Marc Chevrel; Rory O'Neill; Craig Boothby; and Robert Gofton, CEO at Nuclear Institute Across the last eight decades, the Springfields site has supported the UK nuclear fleet, manufacturing more than eight million AGR pins, sintering and pressing over 5
HistoSonics Treats First Patients Evaluating the Edison® Histotripsy System for the Treatment of Benign Prostatic Hyperplasia (BPH)30.3.2026 14:00:00 CEST | Press release
HistoSonics, the developer of the Edison® Histotripsy System and novel histotripsy therapy platform, today announced the successful treatments of the first patients in WOLVERINE, a prospective feasibility trial evaluating the Edison® Histotripsy System for the treatment of benign prostatic hyperplasia (BPH) at Prince of Wales Hospital in Hong Kong, a teaching hospital for The Chinese University of Hong Kong. The Edison System is a novel, non-invasive, image guided platform that uses the mechanical properties of focused ultrasound, called histotripsy, to destroy unwanted tissue without the need for invasive procedures, and with potentially fewer side effects than traditional, invasive therapies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260330349844/en/ HistoSonics Non-Invasive Edison Histotripsy System. Image credit: HistoSonics WOLVERINE is a prospective, multi-center, single-arm feasibility trial designed to evaluate
Biocytogen Grants Taisho Pharmaceutical a License to its RenNano® Fully Human Heavy Chain-Only Antibody Discovery Platform30.3.2026 13:00:00 CEST | Press release
Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (Biocytogen, SSE: 688796; HKEX: 02315), a global biotechnology company that drives the research and development of novel antibody-based drugs with innovative technologies, today announced that it has entered into a platform license agreement with Taisho Pharmaceutical Co., Ltd. (“Taisho”), granting Taisho the right to access and use Biocytogen’s proprietary RenNano® fully human heavy chain-only antibody (HCAbs) discovery platform for its internal research and development programs. Under the terms of the agreement, Taisho will leverage RenNano® mice to enable the generation and screening of fully human HCAbs in vivo and to support downstream research associated with antibody discovery. Financial terms of the agreement have not been disclosed. “We are very pleased to enter into this collaboration with Taisho,” said Dr. Yuelei Shen, President and CEO of Biocytogen. “RenNano® is a robust and powerful fully human VHH discovery platform that pro
Meiji Seika Pharma Invests in Centivax to Develop Next Generation Universal Vaccine Platform30.3.2026 13:00:00 CEST | Press release
Meiji Seika Pharma Co., Ltd. (Head Office: Chuo-ku, Tokyo, President and Representative Director: Toshiaki Nagasato) today announced a strategic investment in Centivax, Inc. (Head Office: South San Francisco, CA, USA), a biotechnology company developing next-generation vaccines and therapies for universal protection against highly diverse targets. Centivax’s lead program includes a universal seasonal influenza vaccine (Centi-Flu 01) currently in a Phase 1 clinical study. Unlike conventional seasonal flu vaccines, which must be manufactured annually based on recommended candidate vaccine viruses, Centivax’s platform focuses both antibody and cellular immune responses on conserved regions of the influenza virus that cannot mutate and are shared across strains and distant subtypes. This approach aims to generate broad, consistent, and durable immunity against both seasonal and pandemic influenza. Meiji’s strategic investment aims to accelerate the advancement of Centi-Flu 01 and further a
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom